Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein kinase cAMP-dependent type II regulatory subunit beta (PRKAR2B)
- Target
- PRKAR2B
- Molecular classification
- Enzyme regulator (regulatory subunit), Signal transduction modulator, Protein complex component
01
Overview
Protein kinase cAMP-dependent type II regulatory subunit beta (PRKAR2B) is a regulatory subunit of protein kinase A (PKA), a holoenzyme tetramer involved in cellular signal transduction via cAMP. The inactive PKA holoenzyme consists of two regulatory (R) subunits and two catalytic (C) subunits. Upon cAMP binding, PRKAR2B releases active catalytic subunits, enabling phosphorylation of downstream targets. PRKAR2B is involved in metabolic regulation, immunity, and neuronal signaling, interacts with various anchoring proteins for cellular localization, and modulates transcriptional regulators such as CREB1. Dysregulation or mutation of PRKAR2B is linked to multiple disease states, including cancer and metabolic disorders[2][3][6][7][8].
- Other names
- cAMP-dependent protein kinase type II-beta regulatory subunitProtein kinase A regulatory subunit II betacAMP-dependent protein kinase RIIβ subunitKAP3
02
Mechanism of action
Drugs/ligands bind to the regulatory subunit and trigger release and activation of catalytic subunits of PKA; Modulation of cAMP binding alters downstream signaling and kinase activity
03
Biological functions
Signal transductionRegulation of protein phosphorylationcAMP signalingRegulation of lipid and glucose metabolismSuppression of CREB1-mediated transcription in T cellsRegulation of energy balance and adiposity
04
Disease associations
Cancer (e.g., hematologic cancer, fibrolamellar carcinoma)Metabolic disease (energy balance, obesity)Neurological/psychiatric associations (behavioral responses to antipsychotics)Other
05
Safety considerations
Manipulation of PKA pathway may affect multiple signaling cascades leading to broad systemic effectsPotential impact on metabolic regulation, cardiac function, and neurological processes
06
Interacting drugs
Cyclic adenosine monophosphate (cAMP)
07
Biomarkers
PRKAR2B expression or mutations (potential in energy metabolism disorders, cancer; limited current clinical biomarker use)
Beyond the preview
Go deeper on Protein kinase cAMP-dependent type II regulatory subunit beta (PRKAR2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein kinase cAMP-dependent type II regulatory subunit beta (PRKAR2B).